Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166716 | 0.85 | SIGMAR1 (0.68) | SIGMAR1THRBHTR1ACYP1A2CYP2D6 | |
| SCHEMBL4163306 | 0.85 | KDM4E (0.54) | SIGMAR1TP53THRBCNR1KDM4E | |
| Bromide SCHEMBL4169172 | 0.84 | SIGMAR1 (0.66) | SIGMAR1THRBHTR1ACYP1A2CYP2D6 | |
| SCHEMBL4169180 | 0.82 | SIGMAR1 (0.61) | SIGMAR1THRBCYP1A2CYP2D6TMEM97 | |
| SCHEMBL2293063 | 0.78 | SIGMAR1 (0.69) | SIGMAR1HTR1ACYP1A2CYP2D6TMEM97 | |
| SCHEMBL10576036 | 0.78 | ALDH1A1 (0.81) | SIGMAR1CNR1KDM4EALDH1A1LMNA | |
| SCHEMBL12120406 | 0.78 | KDM4E (0.61) | SIGMAR1TP53THRBCNR1KDM4E | |
| SCHEMBL2293058 | 0.76 | SIGMAR1 (0.59) | SIGMAR1HTR1ACYP1A2CYP2D6TMEM97 | |
| SCHEMBL13118001 | 0.75 | KDM4E (0.64) | TP53THRBCNR1KDM4EALDH1A1 | |
| SCHEMBL13621171 | 0.74 | KDM4E (0.59) | TP53CNR1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| EP-1981849-A1 | HETEROCYCLIC COMPOUNDS | LEK Pharmaceuticals D.D. (SI) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | CYP51A1, DHCR7, LSS | SIGMAR1 1948/4885TP53 4824/4885THRB 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.